🇺🇸 Homoharringtonine in United States

116 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Bone Marrow Failure — 29 reports (25%)
  2. Off Label Use — 13 reports (11.21%)
  3. Product Use In Unapproved Indication — 13 reports (11.21%)
  4. Myelosuppression — 12 reports (10.34%)
  5. Nausea — 11 reports (9.48%)
  6. Lung Infection — 10 reports (8.62%)
  7. Vomiting — 9 reports (7.76%)
  8. Drug Ineffective — 7 reports (6.03%)
  9. Hepatic Function Abnormal — 6 reports (5.17%)
  10. Infection — 6 reports (5.17%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is Homoharringtonine approved in United States?

Homoharringtonine does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Homoharringtonine in United States?

ChemGenex Pharmaceuticals is the originator. The local marketing authorisation holder may differ — check the official source linked above.